Reuters logo
BRIEF-Oryzon presents new preclinical data of ORY-2001 therapeutic activity in multiple sclerosis
February 27, 2017 / 1:17 PM / 10 months ago

BRIEF-Oryzon presents new preclinical data of ORY-2001 therapeutic activity in multiple sclerosis

Feb 27 (Reuters) - Oryzon Genomics Sa

* Oryzon Genomics SA - data shows ORY-2001, given in wide range of doses provides long lasting protection in terms of survival, mobility of animals even at lower doses

* Oryzon Genomics SA - ongoing Phase I trial with ORY-2001, initiated in early 2016 will be completed in a few weeks Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below